CollPlant Biotechnologies (CLGN) Cost of Revenue (2017 - 2026)

CollPlant Biotechnologies (CLGN) has 10 years of Cost of Revenue data on file, last reported at $316000.0 in Q1 2026.

• Quarterly Cost of Revenue rose 68.09% year-over-year to $316000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $963000.0 (down 24.05% YoY) and the FY2025 annual result came in at $835000.0, down 48.62% from the prior year.
• Cost of Revenue improved to $316000.0 in Q1 2026, from $192000.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $773000.0 in Q4 2023 to a low of $31000.0 in Q1 2022.
• A 5-year average of $303941.2 and a median of $272000.0 in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue sank 96.5% — and 2023, when it soared 1330.23%.
• Tracing CLGN's Cost of Revenue over 5 years: stood at $62000.0 in 2022, then jumped by 1146.77% to $773000.0 in 2023, then sank by 64.81% to $272000.0 in 2024, then dropped by 29.41% to $192000.0 in 2025, then surged by 64.58% to $316000.0 in 2026.
• The last three Cost of Revenue figures came in at $316000.0 (Q1 2026), $192000.0 (Q4 2025), and $269000.0 (Q3 2025), per Business Quant data.